Aduro Biotech
740 Heinz Avenue
Berkeley
California
94710
United States
Tel: 510-848-4800
Website: http://www.aduro.com/
About Aduro Biotech
Aduro Biotech, Inc. is a Berkeley, California-based immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases.
Aduro's three proprietary technology platforms, Live, Attenuated Double-Deleted Listeria (LADD), STING Pathway Activators, and B-select monoclonal antibodies, are designed to harness the body's natural immune system. Our extensive pipeline of product candidates derived from these platforms are currently being investigated in a variety of cancer indications and have the potential to expand into autoimmune and infectious diseases.
Aduro's LADD technology platform is based on proprietary attenuated strains of Listeria that have been engineered to express tumor-associated antigens to induce specific and targeted immune responses. This platform is being developed as a treatment for multiple indications, including mesothelioma, gastric/esophageal, ovarian, lung and prostate cancers. Additionally, a personalized form of LADD, or pLADD, is being developed utilizing tumor neoantigens that are specific to an individual patient’s tumor.
Aduro's STING Pathway Activator platform is designed to activate the intracellular STING receptor, resulting in a potent tumor-specific immune response. ADU-S100 is the first STING Pathway Activator compound to enter the clinic and is currently being evaluated in a Phase 1 study in patients with cutaneously accessible metastatic solid tumors or lymphomas.
Aduro’s B-select monoclonal antibody platform includes a number of immune modulating assets in research and preclinical development, including BION-1301, an anti-APRIL antibody. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms.
Learn more at www.aduro.com.
Aduro Biotech. Pioneering Immunotherapy. Transforming Lives.
148 articles about Aduro Biotech
-
Aduro Biotech To Present At J.P. Morgan Healthcare Conference
1/8/2016
-
Aduro Biotech To Present At Oppenheimer Healthcare Conference
12/2/2015
-
Aduro Biotech To Present At NASDAQ Investor Conference
11/30/2015
-
Aduro Biotech Drops After Quietly Disclosing Patient in Top Phase II Program Developed Serious Infection
11/30/2015
-
Aduro Biotech Confirms All Clinical Trials Continue Unaltered And As Planned
11/25/2015
-
Aduro Biotech Receives Orphan Drug Designation In The European Union For CRS-207 For The Treatment Of Mesothelioma
11/23/2015
-
Aduro Biotech Announces Third Quarter 2015 Financial Results
11/23/2015
-
Aduro Biotech Europe’s Chief Scientific Officer, Andrea Van Elsas, Ph.D. Featured As Keynote Speaker On Immunomodulatory Antibodies At ESMO Symposium On Immuno-Oncology 2015
11/20/2015
-
Aduro Biotech Establishes European Subsidiary
11/20/2015
-
Aduro Biotech Receives Milestone Payment From Janssen Pharmaceutical For Submission Of Investigational New Drug Application For ADU-741 In Prostate Cancer
11/18/2015
-
Aduro Biotech Announces Five Poster Presentations At The Society Of Immunotherapy Of Cancer Annual Meeting
11/9/2015
-
Aduro Biotech To Present At Credit Suisse Healthcare Conference
11/5/2015
-
Aduro Biotech Receives Milestone Payment From Janssen Biotech Inc. For Acceptance Of Investigational New Drug Application For ADU-214 In Lung Cancer
10/29/2015
-
Aduro Biotech And Protein Potential LLC Present Data Demonstrating Novel Vaccine Offers 100% Protection In Malarial Model
10/28/2015
-
Aduro Biotech Receives Milestone Payment From Janssen Biotech Inc. For Submission Of Investigational New Drug Application For ADU-214 In Lung Cancer
10/9/2015
-
Aduro Biotech Announces Phase 1b Mesothelioma Trial Featured In Spotlight Poster At ESMO/ECC
9/28/2015
-
Fast-Growing Aduro Biotech Bags Dutch Antibody Discovery Firm for $32.5 Million
9/25/2015
-
Aduro Biotech To Participate In Leerink Partners Immuno-Oncology Roundtable
9/23/2015
-
Berkeley’s Aduro Biotech Isn’t Just on the Mark — It’s on the Move, Too
9/21/2015
-
Aduro Biotech Appoints Blaine Templeman As Executive Vice President, General Counsel And Secretary
9/21/2015